Fidelity Disruptive Medicine Fund

Frequently Asked Questions About FMEDX

What does FMEDX invest in?

The fund primarily directs at least 80% of its total assets into companies that are leading advancements in the medical sector. Its core investments largely consist of equity instruments. According to the Adviser, "disruptive medicine" companies encompass, but are not limited to, those engaged in fields such as robotic surgical procedures, gene therapy, genomic research, treatments for rare conditions, cutting-edge medical devices and apparatus, immunotherapy, digital healthcare platforms, and initiatives promoting consumer well-being. It is important to note that this fund operates as a non-diversified portfolio.

What is the expense ratio of FMEDX?

An expense ratio for Fidelity Disruptive Medicine Fund (FMEDX) is not available from our data sources — neither our market-data feed nor the SEC's structured prospectus and annual-report datasets report one for this share class. The fund's prospectus on the issuer's site carries the authoritative fee.

How big is FMEDX?

Fidelity Disruptive Medicine Fund (FMEDX) manages $43.2M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is FMEDX actively managed or an index fund?

FMEDX's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was FMEDX launched?

Fidelity Disruptive Medicine Fund (FMEDX) launched in April 2020 and is managed by Fidelity.

How has FMEDX performed?

FMEDX's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.